GlassScriptPhysician profile
Akshar N Patel
NPI 1902199391
$2,118.57
in general payments reported to CMS, 2019-2025
37 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $71.51 · 2021: $278 · 2022: $303 · 2023: $411 · 2024: $156 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $343.93 | 2019-2025 | Spaceoar Vue System - 10ml |
| Celgene Corporation | $123.96 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $95.13 | 2019-2022 | |
| Daiichi Sankyo INC. | $91.52 | 2022-2024 | Enhertu |
| Varian Medical Systems, INC. | $90.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.57 | 2019-2025 | |
| Amgen INC. | $86.46 | 2022-2023 | Xgeva, Lumakras, Nplate |
| Merck Sharp & Dohme LLC | $83.12 | 2019-2023 | Keytruda, Lynparza |
| Foundation Medicine, INC. | $81.69 | 2019 | |
| Sun Pharmaceutical Industries INC. | $80.42 | 2021 | |
| Glaxosmithkline, LLC. | $71.49 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $67.48 | 2023-2024 | Orgovyx |
| Myovant Sciences INC. | $64.67 | 2021-2022 | |
| Seagen INC. | $55.31 | 2022-2023 | Tukysa, Padcev |
| Exelixis INC. | $51.17 | 2021-2023 | Cabometyx |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $50.80 | 2023 | Krazati |
| Blue Earth Diagnostics | $44.41 | 2024 | |
| Palette Life Sciences, INC. | $43.71 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $43.51 | 2022-2023 | Lynparza |
| Puma Biotechnology, INC. | $42.09 | 2019-2020 | |
| Tactile Systems Technology INC | $38.40 | 2022-2025 | Nimbl, Flexitouch Plus |
| Janssen Biotech, INC. | $36.24 | 2019-2020 | |
| Genentech USA, INC. | $35.31 | 2023 | Tecentriq, Alecensa, Avastin |
| Avyxa Pharma, LLC | $34.69 | 2025 | |
| Teleflex LLC | $29.53 | 2024 | |
| Pfizer INC. | $28.00 | 2024 | |
| Tersera Therapeutics LLC | $27.72 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $27.01 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.65 | 2025 | Libtayo |
| Agios Pharmaceuticals, INC. | $19.42 | 2019 | |
| Genzyme Corporation | $19.03 | 2021 | |
| Gilead Sciences, INC. | $18.27 | 2021 | |
| Heron Therapeutics, INC. | $16.72 | 2020 | |
| Clovis Oncology, INC. | $15.79 | 2019 | |
| Lilly USA, LLC | $15.70 | 2023 | Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $14.89 | 2019 | |
| Telix Pharmaceuticals | $14.66 | 2024 | Illuccix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.